GFM
OKUR

GF Fund Management’s OnKure Therapeutics OKUR Stock Holding History

GF Fund Management’s Portfolio OKUR Stock Details OKUR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-271
Closed -$745 – 706
2025
Q3 		$745 Sell
271
-42
-13% -$104 ﹤0.01% 629
2025
Q2 		$748 Hold
313
– – ﹤0.01% 659
2025
Q1 		$1.35K Buy
313
+47
+18% +$264 ﹤0.01% 658
2024
Q4 		$2.29K Buy
+266
New +$4.03K ﹤0.01% 635

Other funds holding OKUR

ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
SC
Shay Capital New York $1.2B AUM 37.47% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
SG
StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return

GF Fund Management's OKUR Position: Q4 2025 in Review

GF Fund Management sold out of OnKure Therapeutics (OKUR) in Q4 2025, closing a stake of 271 shares — an estimated $745 sold.

GF Fund Management first reported a position in OKUR in Q4 2024 and held it in 4 quarters. The position peaked at $2.29K in Q4 2024. 44 funds tracked by Wall St. Rank hold OKUR as of Q4 2025.

  • GF Fund Management reported no remaining OnKure Therapeutics position as of Q4 2025 after selling out during the quarter.
  • GF Fund Management sold 271 OnKure Therapeutics shares in Q4 2025, an estimated $745.
  • GF Fund Management first reported a position in OnKure Therapeutics in Q4 2024 and held it in 4 quarters.
  • GF Fund Management's OnKure Therapeutics position peaked at $2.29K in Q4 2024.
  • 44 funds tracked by Wall St. Rank held OnKure Therapeutics as of Q4 2025.

Based on GF Fund Management's 13F filing for Q4 2025, filed 27 Jan 2026.